Accessibility Menu
Immunovia Ab (publ) logo

Immunovia Ab (publ)(OTC) IMMVF

Market Cap$13.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-100%
5 Year-100%
1 Year-60%
1 Month+0%
$0.02
+0.00%
+0.00Today
Immunovia Ab (publ) last closing stock price
MetricPriceDate
Last closeUSD 0.022026-08-04
Immunovia Ab (publ) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.022026-03-18
1 month+0%USD 0.022026-03-18
3 month+0%USD 0.022026-03-18
Year to date+0%USD 0.022025-12-31
1 year-60%USD 0.052024-12-13
3 year-99.32%USD 2.932023-06-20
5 year-99.83%USD 11.702021-07-28
Since inception-99.89%USD 17.762019-06-28

Immunovia Ab (publ) Financials at a Glance

Market Cap

$13.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

SEK 1.21M

Net Income (TTM)

-SEK 88.02M

EPS (TTM)

-$0.02

P/E Ratio

-1.09

Dividend

$0.00

Beta (Volatility)

1.08 (Average)

Price

$0.02

Volume

150

Open

$0.02

Previous Close

$0.02

Daily Range

$0.02 - $0.02

52-Week Range

$0.02 - $0.15

Estimated Earnings Date

Nov 5, 2026

IMMVF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Immunovia Ab (publ)

Immunovia AB is a pioneering company focused on developing innovative diagnostic methods for complex cancers and autoimmune diseases. Utilizing its advanced technology platform, IMMray, the company aims to enhance early cancer detection, predict disease progression, and monitor treatment responses.

Products and Services
  • IMMray technology for early cancer diagnosis
  • Diagnostic solutions for autoimmune diseases
  • Research and development in cancer progression monitoring
Growth Outlook
  • Recent quarterly revenue increased to 372,725 SEK
  • Cash reserves of 55.9 million SEK support ongoing R&D efforts
  • Strong market potential in early cancer detection and monitoring
Financial Highlights
  • Trailing twelve months (TTM) revenue of 1.1 million SEK
  • Current ratio of 3.05 indicates strong liquidity
  • Net income for Q1 2026 reported at -18.4 million SEK
Immunovia AB operates in the healthcare sector, specifically within the medical and pharmaceutical industry. The company has made significant strides in developing its IMMray technology, which is designed to improve the accuracy and speed of cancer diagnostics. The recent quarterly revenue growth reflects the increasing demand for innovative diagnostic solutions, positioning Immunovia favorably in a competitive market. The company's financial health is underscored by a robust current ratio, indicating a strong ability to meet short-term obligations. However, the net income figures highlight ongoing challenges, as the company continues to invest heavily in research and development. With substantial cash reserves, Immunovia is well-equipped to navigate these challenges while pursuing its mission to revolutionize cancer diagnostics. Overall, Immunovia AB presents a compelling opportunity for investors interested in the intersection of healthcare innovation and market growth potential.
AI Generated • Jul 30, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

18

CEO

Jeff Borcherding, MBA

Website

www.immunovia.com

Headquarters

Lund, SN 223 63, SE

IMMVF Financials

Key Financial Metrics (TTM)

Gross Margin

-1309.75%

Operating Margin

-6830.25%

Net Income Margin

-7300.33%

Return on Equity

-279.07%

Return on Capital

-122.96%

Return on Assets

-183.90%

Earnings Yield

-91.74%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$13.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

672.67M

Volume

150

Avg. Volume

2.381

Financials (TTM)

Gross Profit

-SEK 15.81M

Operating Income

-SEK 81.78M

EBITDA

-SEK 57.86M

Operating Cash Flow

-SEK 77.05M

Capital Expenditure

-SEK 5.56M

Free Cash Flow

-SEK 82.61M

Cash & ST Invst.

SEK 34.60M

Total Debt

SEK 3.27M

Immunovia Ab (publ) Performance Analysis

Immunovia Ab (publ) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31SEK 113,14315.1%
20232023-12-31SEK 148,36231.1%
20242024-12-31SEK 88,057-40.6%
20252025-12-31SEK 69,844-20.7%
Immunovia Ab (publ) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3012.2%
Q42025-12-31249.6%
Q12026-03-315.6%
Q22026-06-302.2%
Immunovia Ab (publ) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31SEK -0.26-8.6%
20232023-12-31SEK -0.299.9%
20242024-12-31SEK -0.07-76.5%
20252025-12-31SEK -0.04-36.6%
Immunovia Ab (publ) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3045.1%
Q42025-12-3158.0%
Q12026-03-3114.9%
Q22026-06-30-9.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

SEK 381.00K

+323.3%

Gross Profit

SEK 139.00K

+54.4%

Gross Margin

36.48%

N/A

Market Cap

$13.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.03M

N/A

Employees

13

N/A

Net Income

-SEK 22.83M

+44.4%

EBITDA

-SEK 22.09M

-12.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

SEK 34.60M

+18.2%

Total Debt

SEK 3.27M

+600.2%

Accounts Receivable

SEK 2.84M

+712.7%

Inventory

SEK 549.00K

N/A

Long Term Debt

SEK 0.00

N/A

Short Term Debt

SEK 6.51M

+1294.4%

Return on Assets

-1.84%

N/A

Return on Invested Capital

-3.50%

N/A

Free Cash Flow

-SEK 20.39M

-12.4%

Operating Cash Flow

-SEK 20.39M

-12.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
UEECUnited Health Products, Inc.
$0.04+2.38%
ASAPFAurora Spine Corporation
$0.14-12.06%
ZHCLFZenith Capital Corp.
$0.02-33.33%
PPCBPropanc Biopharma, Inc.
$1.22+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About IMMVF

What is the current price of Immunovia Ab (publ)?

Immunovia Ab (publ) is trading at $0.02 per share.

What is the 52-week range for Immunovia Ab (publ)?

Over the past 52 weeks, Immunovia Ab (publ) has traded between $0.02 and $0.15.

How much debt does Immunovia Ab (publ) have?

As of the most recent reporting period, Immunovia Ab (publ) reported total debt of SEK 337.87K.

How much cash does Immunovia Ab (publ) have on hand?

Immunovia Ab (publ) reported SEK 3.61M in cash and cash equivalents in its most recent financial results.

What is Immunovia Ab (publ)’s dividend yield?

Immunovia Ab (publ) does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services